Please use this identifier to cite or link to this item:
Title: Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
Issue Date: Aug-2015
Citation: Oncologist.2015 Aug;(20)8:864-72
Abstract: Cardiotoxicity represents a major limitation for the use of anthracyclines or trastuzumab in breast cancer patients. Data from longitudinal studies of diastolic dysfunction (DD) in this group of patients are scarce. The objective of the present study was to assess the incidence, evolution, and predictors of DD in patients with breast cancer treated with anthracyclines.
PMID: 26185196
Rights: openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
PMC4524754.pdf1.73 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.